Arcus Biosciences (RCUS) Net Income (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly Net Income came in at -$128.0 million in Q1 2026, down 14.29% year-on-year from -$149.3 million in Q1 2025, and down 20.75% quarter-over-quarter from -$106.0 million in Q4 2025.
Arcus Biosciences (RCUS) Net Income (2017 - 2026) Analysis & Trends
Arcus Biosciences' Net Income history runs 10 years deep, the most recent figure standing at -$128.0 million for Q1 2026.
- On a quarterly basis, Net Income fell 14.29% year-over-year to -$128.0 million in Q1 2026; TTM through Mar 2026 was -$369.0 million, a 5.63% increase from a year earlier, with the FY2025 full-year figure at -$353.0 million, down 24.73% from the prior year.
- Net Income declined to -$128.0 million in Q1 2026 per RCUS's latest filing, from -$106.0 million in the prior quarter.
- Across five years, Net Income topped out at -$4.0 million in Q1 2024 and bottomed at -$135.0 million in Q3 2025.
- The 5-year median for Net Income is -$80.5 million (2023), against an average of -$83.6 million.
- Across the five-year window, Net Income soared 95.0% in 2024 and sank 2700.0% in 2025, its largest moves.
- Year by year, Net Income stood at -$67.0 million in 2022, then declined by 20.9% to -$81.0 million in 2023, then slipped by 16.05% to -$94.0 million in 2024, then declined by 12.77% to -$106.0 million in 2025, then dropped by 20.75% to -$128.0 million in 2026.
- Per Business Quant, the three latest RCUS Net Income figures stand at -$128.0 million (Q1 2026), -$106.0 million (Q4 2025), and -$135.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Arcus Biosciences | 3.73 Bn | 2.90 Bn | - | -128.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.00 Mn |
| Dec 31, 2025 | -106.00 Mn |
| Sep 30, 2025 | -135.00 Mn |
| Mar 31, 2025 | -112.00 Mn |
| Dec 31, 2024 | -94.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Mar 31, 2024 | -4.00 Mn |
| Dec 31, 2023 | -81.00 Mn |
| Sep 30, 2023 | -71.00 Mn |
| Jun 30, 2023 | -75.00 Mn |
| Mar 31, 2023 | -80.00 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -67.00 Mn |
| Mar 31, 2022 | -68.00 Mn |
| Dec 31, 2021 | 279.54 Mn |
| Sep 30, 2021 | -77.98 Mn |
| Jun 30, 2021 | -75.97 Mn |
| Mar 31, 2021 | -72.59 Mn |